Drug stops spread of cancer in trial patients

Recipients of targeted gene treatment see their tumours shrink or stabilise

A new type of cancer treatment which kills malignant cells but leaves healthy cells unscathed has shown remarkable promise in its first trial.

More than half the 60 patients who received the targeted treatment saw their tumours shrink or stabilise, despite having previously tried other therapies which had failed to curb the progress of their disease. One patient who had advanced cancer is still in remission after two years.

The findings are announced today in the New England Journal of Medicine, which has taken the unusual decision to publish the small trial at such an early stage because of its "important results". An accompanying editorial says they "point to a new direction in the development of anti-cancer drugs".

The announcement comes five days after scientists at the Mayo Clinic in the US reported success with a new drug for prostate cancer. Two patients who had "inoperable" tumours were treated with the drug ipilimumab, a monoclonal antibody that stimulates the immune system. After one infusion, their tumours shrank enough to be surgically removed and both men have made a full recovery.

The latest development involves a different drug, olaparib, which works in a different way by targeting the genetic defect that causes cells to turn cancerous. In a process called "synthetic lethality", the drug has been engineered to chemically inhibit one type of gene, which then acts with the abnormal cancer gene to kill cancer cells in which both are present.

Initial tests have been carried out in patients with inherited breast, ovarian and prostate cancer caused by mutations in the BRCA1 and BRCA2 genes. People with these genetic mutations – about one in 500 people – have a high risk of developing cancer, of up to 80 per cent in the case of breast cancer.

Johann de Bono, a scientist at the Institute of Cancer Research and the leader of the study conducted in the UK and the Netherlands, said the trial showed "very impressive results".

"It's giving patients who have already tried many conventional treatments long periods of remission, free from the symptoms of cancer or major side effects." Professor Stan Kaye, the joint lead researcher from the institute, said: "This is a very important drug for the the treatment of BRCA1/2-related cancer. The next step is to test the drug on other more common types of ovarian and breast cancers where we hope it will be just as effective."

Julian Lewis, 62, who was diagnosed in 2004 with prostate cancer which had spread to his bones, has been on olaparib for two years. The drug has held his prostate cancer in check and the cancer in his bones "seems almost to have disappeared", he said.

Married with three daughters, he lives in Oxford and works as a cancer researcher himself. He is a BRCA2 mutation carrier and his sister died of ovarian cancer.

"It has always been the dream of cancer research to discover drugs that will kill the cancer cells while leaving healthy cells unharmed," he said.

"Now we have the tools in terms of genes to discover what has gone wrong in the cells of a cancer to make them misbehave. If you can pinpoint the key mutation that makes them dangerously different, you can use that to kill the cells selectively. In other words you can turn the weapon of the mischief-maker against the mischief-maker itself."

The drug is now being tested in further larger trials across the world.

Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
Life and Style
Powdered colors are displayed for sale at a market ahead of the Holi festival in Bhopal, India
techHere's what you need to know about the riotous occasion
Arts and Entertainment
Larry David and Rosie Perez in ‘Fish in the Dark’
theatreReview: Had Fish in the Dark been penned by a civilian it would have barely got a reading, let alone £10m advance sales
News
Details of the self-cleaning coating were published last night in the journal Science
science
News
Approved Food sell products past their sell-by dates at discounted prices
i100
News
Life-changing: Simone de Beauvoir in 1947, two years before she wrote 'The Second Sex', credited as the starting point of second wave feminism
peopleHer seminal feminist polemic, The Second Sex, has been published in short-form to mark International Women's Day
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Finance Assistant / Credit Controller

    £16000 - £18000 per annum: Recruitment Genius: They are an award-winning digit...

    Ashdown Group: Senior VMware Platform Engineer - VMware / SAN / Tier3 DC

    £45000 - £55000 per annum + benefits: Ashdown Group: Senior VMware Platform En...

    Recruitment Genius: Purchasing Assistant

    £10000 - £16000 per annum: Recruitment Genius: A distributor of specialist ele...

    Recruitment Genius: Sales Ledger Assistant

    £17000 - £19000 per annum: Recruitment Genius: A distributor of specialist ele...

    Day In a Page

    Homeless Veterans campaign: Donations hit record-breaking £1m target after £300,000 gift from Lloyds Bank

    Homeless Veterans campaign

    Donations hit record-breaking £1m target after huge gift from Lloyds Bank
    Flight MH370 a year on: Lost without a trace – but the search goes on

    Lost without a trace

    But, a year on, the search continues for Flight MH370
    Germany's spymasters left red-faced after thieves break into brand new secret service HQ and steal taps

    Germany's spy HQ springs a leak

    Thieves break into new €1.5bn complex... to steal taps
    International Women's Day 2015: Celebrating the whirlwind wit of Simone de Beauvoir

    Whirlwind wit of Simone de Beauvoir

    Simone de Beauvoir's seminal feminist polemic, 'The Second Sex', has been published in short-form for International Women's Day
    Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

    Mark Zuckerberg’s hiring policy might suit him – but it wouldn’t work for me

    Why would I want to employ someone I’d be happy to have as my boss, asks Simon Kelner
    Confessions of a planespotter: With three Britons under arrest in the UAE, the perils have never been more apparent

    Confessions of a planespotter

    With three Britons under arrest in the UAE, the perils have never been more apparent. Sam Masters explains the appeal
    Russia's gulag museum 'makes no mention' of Stalin's atrocities

    Russia's gulag museum

    Ministry of Culture-run site 'makes no mention' of Stalin's atrocities
    The big fresh food con: Alarming truth behind the chocolate muffin that won't decay

    The big fresh food con

    Joanna Blythman reveals the alarming truth behind the chocolate muffin that won't decay
    Virginia Ironside was my landlady: What is it like to live with an agony aunt on call 24/7?

    Virginia Ironside was my landlady

    Tim Willis reveals what it's like to live with an agony aunt on call 24/7
    Paris Fashion Week 2015: The wit and wisdom of Manish Arora's exercise in high camp

    Paris Fashion Week 2015

    The wit and wisdom of Manish Arora's exercise in high camp
    8 best workout DVDs

    8 best workout DVDs

    If your 'New Year new you' regime hasn’t lasted beyond February, why not try working out from home?
    Paul Scholes column: I don't believe Jonny Evans was spitting at Papiss Cissé. It was a reflex. But what the Newcastle striker did next was horrible

    Paul Scholes column

    I don't believe Evans was spitting at Cissé. It was a reflex. But what the Newcastle striker did next was horrible
    Miguel Layun interview: From the Azteca to Vicarage Road with a million followers

    From the Azteca to Vicarage Road with a million followers

    Miguel Layun is a star in Mexico where he was criticised for leaving to join Watford. But he says he sees the bigger picture
    Frank Warren column: Amir Khan ready to meet winner of Floyd Mayweather v Manny Pacquiao

    Khan ready to meet winner of Mayweather v Pacquiao

    The Bolton fighter is unlikely to take on Kell Brook with two superstar opponents on the horizon, says Frank Warren
    War with Isis: Iraq's government fights to win back Tikrit from militants - but then what?

    Baghdad fights to win back Tikrit from Isis – but then what?

    Patrick Cockburn reports from Kirkuk on a conflict which sectarianism has made intractable